On Tuesday AstraZeneca voluntarily suspended clinical trials in the UK for the University of Oxford-developed vaccine candidate after an event of potential adverse side effect came to notice. The Indian arm of the trials continues its process.
A lot is riding on what is dubbed as one of the frontrunners for Covid-19 vaccine. A look at what it means for India and Serum Institute: Why was the AstraZeneca-Oxford University trial paused? British-Swedish drug major AstraZeneca on Tuesday decided to halt clinical trials of AZD1222, a vaccine candidate developed by the University of ...
TO READ THE FULL STORY, SUBSCRIBE NOW NOW AT JUST Rs
Key stories on business-standard.com are available to premium subscribers only.
Already a premium subscriber? LOGIN NOW
Copyrights © 2020 Business Standard Private Ltd. All rights reserved.
